Clinical Trials List
2025-02-28 - 2029-08-15
Phase III
Recruiting4
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 曹朝榮 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 林建良 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 林正耀 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 陳彥勳 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tung-Liang Lin Division of Hematology & Oncology
- 張 鴻 Division of Hematology & Oncology
- 洪玉馨 Division of Hematology & Oncology
- HSUAN JEN SHIH Division of Hematology & Oncology
- 蘇羿囷 Division of Hematology & Oncology
- 王元欽 Division of Hematology & Oncology
- 高小雯 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 李思慧 Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
- CHENG-HONG TSAI Division of General Internal Medicine
- Chien-Chin Lin Division of General Internal Medicine
- - - Division of General Internal Medicine
- 袁章祖 Division of Others
- Wen-Chien Chou Division of General Internal Medicine
- YAO CHI-YUAN Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- 田豐銘 Division of General Internal Medicine
- Huai-Hsuan Huang Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
600 participants
